Entheon Biomedical CSE: (ENBI); OTCMKTS: (ENTBF); FSE: (1XU1) is a drug discovery and biotechnology company working to validate the therapeutic potential of psychedelic medicines in the context of rigorous clinical study. The company's primary aim is to provide solutions for people battling addiction so they can reclaim their lives and potential. With a primary focus on the DMT molecule, Entheon is developing a unique treatment system as well as highly specialized set of tools to personalize care, from patient assessment to psychedelic treatment and beyond. We believe a comprehensive and holistic approach to care will significantly increases their odds of permanent recovery for those struggling with addiction.
Timothy has a background of leading private ventures in the Service Sector, Investor Relations, Retail and Technology sectors. With a professional emphasis on disruptive technologies that challenge the status quo, Timothy’s passion for the psychedelic space is shaped by firsthand knowledge of the shortcomings of current mental health and addiction treatment options, and through his exposure to psychedelics, which he credits with saving his life.